[1]CurrentPatentAssignee:VERTEXPHARMACEUTICALS(OLD)-WO2005/90334,2005,A2Locationinpatent:Page/Pagecolumn77-78
[1]OrganicLetters,2008,vol.10,p.185-188
[1]Patent:US9487555,2016,B2
[1]CurrentPatentAssignee:VERTEXPHARMACEUTICALS(OLD)-US9487555,2016,B2
[1]Patent:US9487555,2016,B2
Title: Stack JH, et al. IL-converting enzyme/caspase-1 inhibitor VX-765 blocks the hypersensitive response to an inflammatory stimulus in monocytes from familial cold autoinflammatory syndrome patients. J Immunol. 2005 Aug 15;175(4):2630-4.
Title: Wannamaker W, et al. (S)-1-((S)-2-{-(4-amino-3-chloro-phenyl)-methanoyl-amino}-3,3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic acid ((2R,3S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765), an orally available selective interleukin (IL)-converting enzyme/caspase-1 inhibitor, exhibits potent anti-inflammatory activities by inhibiting the release of IL-1beta and IL-18. J Pharmacol Exp Ther. 2007 May;321(2):509-16.
Title: Ravizza T, et al. Inactivation of caspase-1 in rodent brain: a novel anticonvulsive strategy. Epilepsia. 2006 Jul;47(7):1160-8.